Cytosorbents Crp (CTSO)vsEdwards Lifesciences Corp (EW)
CTSO
Cytosorbents Crp
$0.39
-5.94%
HEALTHCARE · Cap: $22.75M
EW
Edwards Lifesciences Corp
$94.37
-1.70%
HEALTHCARE · Cap: $51.66B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 16845% more annual revenue ($6.30B vs $37.20M). EW leads profitability with a 17.4% profit margin vs -31.9%. EW earns a higher WallStSmart Score of 59/100 (C).
CTSO
Avoid24
out of 100
Grade: F
EW
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CTSO.
Margin of Safety
+68.6%
Fair Value
$252.36
Current Price
$94.37
$157.99 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
16.7% revenue growth
Areas to Watch
Trading at 9.8x book value
1.6% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : CTSO
CTSO has a balanced fundamental profile.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : CTSO
The primary concerns for CTSO are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 8.64 is elevated, increasing financial risk.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 48.5x leaves little room for execution misses.
Key Dynamics to Monitor
CTSO profiles as a turnaround stock while EW is a growth play — different risk/reward profiles.
CTSO carries more volatility with a beta of 1.36 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
CTSO generates stronger free cash flow (-1M), providing more financial flexibility.
Bottom Line
EW scores higher overall (59/100 vs 24/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cytosorbents Crp
HEALTHCARE · MEDICAL DEVICES · USA
Cytosorbents Corporation, a critical care focused immunotherapy company, is dedicated to the research, development and commercialization of medical devices with its blood purification technology platform incorporating proprietary adsorbent and porous polymer technology. The company is headquartered in Monmouth Junction, New Jersey.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?